TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Dr. David Ramsay the pick for GBTC’s ‘BETA’ award University of Maryland, Baltimore President Dr. David J. Ramsay will receive the Greater Baltimore Technology Council’s annual award recognizing individuals with deep impacts on the local tech community. feeds.bizjournals.com |
Public Faces Long Wait for Flu Vaccine State and local budget cuts coupled with limits on who can administer the new swine-flu vaccine could hamstring efforts to delivery doses to anyone who wants it. online.barrons.com |
ERT Reports Third Quarter 2009 Results (PR Newswire) eResearchTechnology, Inc. , , a leading provider of centralized ECG, ePRO and other services to the biopharmaceutical, medical device and related industries, announced today results for the third quarter and nine-month period ended September 30, 2009. us.rd.yahoo.com |
Pfizer Forms Cancer Collaboration with Crown Bioscience ChinaBio Today submits: Crown Bioscience, a pre-clinical CRO providing biology services for oncology indications, will collaborate with Pfizer (NYSE: PFE) to research and develop novel drugs for cancers that are prevalent in Asia and remain unaddressed medical needs. Crown will receive an upfront payment and research funding, as well as milestone payments upon achieving preclinical and clinical goals. The companies did not disclose specific financial details of their arrangement.Crown, which is headquartered in Santa Clara, CA, has labs in Carmel, IN, Beijing and Taicang (near Shanghai), the company’s newest facility. The Taicang lab will carry out the work for Pfizer, which will be to discover and advance multiple candidates for clinical development. Crown held a Grand Opening for the new lab this past Sunday. It was attended by 100-200 guests, including many of Pfizer's senior executives. Steve Yang, PhD, Vice-President of Pfizer and Head of R&D-Asia was one of the attendees. Complete Story » seekingalpha.com |
NeoStem: BioInsurance for the Future M.E. Garza submits: When Robin L. Smith M.D., Chairman of the Board and Chief Executive Officer of NeoStem Inc. (AMEX:NBS) first got involved with the company three years ago, it was a four cent stock called “Phase III Medical.” The company was making investments in companies for pieces of royalties and revenues. To its credit, one of the companies Phase III was very interested in helping finance was a tiny company called NeoStem. Now, as the science of stem cells continues to advance, doctors have come to realize that in each of us, stem cells become less and less in quantity and quality. This is cue not only to aging, but also to our environment, the food we eat and various other health factors.Complete Story » seekingalpha.com |